Company newsMRNA
Explain this story: Moderna stock hits 52-week high at 176.75 USD
Moderna's stock has reached a new 52-week high of $176.75 USD, trading at $176.21 USD with a market capitalization of $70.4 billion. This significant surge, reflecting a 510% one-year price total return and a 422% year-to-date increase, is attributed to advancements in its biotechnology sector, particularly its COVID-19 vaccine development. However, InvestingPro analysis advises caution due to high price volatility and expectations of unprofitability this year, suggesting the stock may be overvalued.
OtherInvesting.comSector and industry: HealthcareBiotechnologyTell me moreShow less
We have not explained this story yet. The original headline, summary and link are below.
Moderna's stock has reached a new 52-week high of $176.75 USD, trading at $176.21 USD with a market capitalization of $70.4 billion. This significant surge, reflecting a 510% one-year price total return and a 422% year-to-date increase, is attributed to advancements in its biotechnology sector, particularly its COVID-19 vaccine development. However, InvestingPro analysis advises caution due to high price volatility and expectations of unprofitability this year, suggesting the stock may be overvalued.
Article tone: Positive This describes the words the journalist used. It is not a prediction, and not advice.
Also mentioned:MRK
Published Sep 21, 2026, 14:23 ET · on this site +5d 11h